Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mainwaring

Showing results (451-460 of 465) with videos related to

Pageof 47
Sort By:
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|September 26, 2015
Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Biotechnology and Bioengineering|September 29, 2021
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needsCarina C D Joe, Jinlin Jiang, Thomas Linke, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Research|October 11, 2022
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of MedulloblastomaAnna Borgenvik, Karl O Holmberg, Sara Bolin, et al.
Nature Communications|April 20, 2022
Bird populations most exposed to climate change are less sensitive to climatic variationLiam D Bailey, Martijn van de Pol, Frank Adriaensen, et al.
Ecology|October 31, 2022
Temperature synchronizes temporal variation in laying dates across European hole-nesting passerinesStefan J G Vriend, Vidar Grøtan, Marlène Gamelon, et al.
Pageof 47

Showing results (451-460 of 465) with videos related to

Sort By:
Pageof 47
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|September 26, 2015
Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Biotechnology and Bioengineering|September 29, 2021
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needsCarina C D Joe, Jinlin Jiang, Thomas Linke, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Research|October 11, 2022
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of MedulloblastomaAnna Borgenvik, Karl O Holmberg, Sara Bolin, et al.
Nature Communications|April 20, 2022
Bird populations most exposed to climate change are less sensitive to climatic variationLiam D Bailey, Martijn van de Pol, Frank Adriaensen, et al.
Ecology|October 31, 2022
Temperature synchronizes temporal variation in laying dates across European hole-nesting passerinesStefan J G Vriend, Vidar Grøtan, Marlène Gamelon, et al.
Pageof 47